Retina

Andrew G. Lee, MD, and Drew Carey, MD, discuss how optic disc cupping after optic neuritis reflects nerve and ganglion cell thinning, not disease type, helping distinguish it from glaucoma.

The trial is evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa (RP).

AI reads infant retinal scans to flag lung disease early, while transient vision loss warns of looming stroke and heart events.

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).

Japan fast-tracks MCO-010 optogenetic eye injection as studies show lasting safety and meaningful vision gains in inherited retinal disease.

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice settings, according to Dustin D. French, PhD.

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration.

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

New US patent boosts Nanoscope’s MCO-010 optogenetic therapy as long-term studies show lasting safety and vision gains in retinal disease.

The Part B dose-expansion portion is evaluating SB-007 for the treatment of Stargardt disease.

Optoretinography is an emerging technology used to test light-evoked photoreceptor activity.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.

OCTA shows deep retinal vessel density mirrors thyroid eye disease activity, tying orbital inflammation and muscle thickening to improved monitoring.

Researchers uncover a DNA repair mechanism in Greenland sharks that preserves their vision for centuries, offering insights into longevity and eye health.

According to the company, the FDA’s decision was supported by visual function results from the phase 2 ACUITY trial in ON.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

The novel system converts light into electrical signals to stimulate retinal cells.

Strategies for treatment intervals, drug selection, and patient expectations.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.